The Experts below are selected from a list of 36 Experts worldwide ranked by ideXlab platform

Jia-hong Chen - One of the best experts on this subject based on the ideXlab platform.

  • Univariate Cox regression analysis of 4-year progression-free survival and overall survival of 180 patients with age
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; RR: relative risk; UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

  • Univariate Cox regression analysis of 4-year progression-free survival and overall survival of 108 patients with with old age (≧70) in relation to chemotherapeutic strategies.
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; RR: relative risk; UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

  • The descriptive characteristics and distribution of patients according to chemoregimens.
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    Abbreviations: CEA: carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group performance status; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; No.: number; OXA-based+ 5-FU-based: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; TNM stage: Cancer staging system which was developed and is maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M); UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); w/o: without; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

  • Univariate Cox regression analysis of 4-year progression-free survival and overall survival in relation to patients’ characteristics.
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; CEA: carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group performance status; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; RR: relative risk; TNM stage: Cancer staging system which was developed and is maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M); UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

Richard Pazdur - One of the best experts on this subject based on the ideXlab platform.

  • Tegafur/Uracil + Calcium Folinate in Colorectal Cancer
    Drugs, 1999
    Co-Authors: Paulo M. Hoff, Yvonne Lassere, Richard Pazdur
    Abstract:

    The oral chemotherapeutic agent tegafur/uracil (UFT®) is the first of a new class of anticancer drugs called dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. Tegafur/uracil combines uracil with the fluorouracil prodrug tegafur in a 4: 1 molar ratio. Uracil competitively inhibits the degradation of fluorouracil, which results in the concentration of fluorouracil remaining at sustained levels in both plasma and tumour. Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours. Trials conducted in the US have focused on the combination of tegafur/uracil plus Calcium Folinate (Calcium leucovorin) [ORZEL®]. Several phase I and II trials have evaluated the maximum tolerated dose, pharmacokinetics, efficacy, and safety of this combination in the treatment of colorectal cancer. Results have shown that tegafur/uracil at 300 mg/m^2/day in divided doses given every 8 hours for 28 days provides prolonged exposure to fluorouracil. Furthermore, tegafur/uracil + Calcium Folinate is well tolerated, with dose-limiting toxicity manifesting as diarrhoea. Compared with intravenous fluorouracil plus folinic acid (leucovorin) regimens, tegafur/uracil + Calcium Folinate has similar efficacy with less toxicity and is more convenient because it is an oral regimen. Early studies have also shown potential cost savings because of fewer complications.

  • Tegafur/uracil + Calcium Folinate in colorectal cancer: double modulation of fluorouracil.
    Drugs, 1999
    Co-Authors: Paulo M. Hoff, Yvonne Lassere, Richard Pazdur
    Abstract:

    The oral chemotherapeutic agent tegafur/uracil (UFT®) is the first of a new class of anticancer drugs called dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. Tegafur/uracil combines uracil with the fluorouracil prodrug tegafur in a 4: 1 molar ratio. Uracil competitively inhibits the degradation of fluorouracil, which results in the concentration of fluorouracil remaining at sustained levels in both plasma and tumour. Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours. Trials conducted in the US have focused on the combination of tegafur/uracil plus Calcium Folinate (Calcium leucovorin) [ORZEL®]. Several phase I and II trials have evaluated the maximum tolerated dose, pharmacokinetics, efficacy, and safety of this combination in the treatment of colorectal cancer. Results have shown that tegafur/uracil at 300 mg/m2/day in divided doses given every 8 hours for 28 days provides prolonged exposure to fluorouracil. Furthermore, tegafur/uracil + Calcium Folinate is well tolerated, with dose-limiting toxicity manifesting as diarrhoea. Compared with intravenous fluorouracil plus folinic acid (leucovorin) regimens, tegafur/uracil + Calcium Folinate has similar efficacy with less toxicity and is more convenient because it is an oral regimen. Early studies have also shown potential cost savings because of fewer complications.

  • tegafur uracil Calcium Folinate in colorectal cancer double modulation of fluorouracil
    Drugs, 1999
    Co-Authors: Paulo M. Hoff, Yvonne Lassere, Richard Pazdur
    Abstract:

    The oral chemotherapeutic agent tegafur/uracil (UFT®) is the first of a new class of anticancer drugs called dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. Tegafur/uracil combines uracil with the fluorouracil prodrug tegafur in a 4: 1 molar ratio. Uracil competitively inhibits the degradation of fluorouracil, which results in the concentration of fluorouracil remaining at sustained levels in both plasma and tumour. Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours. Trials conducted in the US have focused on the combination of tegafur/uracil plus Calcium Folinate (Calcium leucovorin) [ORZEL®]. Several phase I and II trials have evaluated the maximum tolerated dose, pharmacokinetics, efficacy, and safety of this combination in the treatment of colorectal cancer. Results have shown that tegafur/uracil at 300 mg/m2/day in divided doses given every 8 hours for 28 days provides prolonged exposure to fluorouracil. Furthermore, tegafur/uracil + Calcium Folinate is well tolerated, with dose-limiting toxicity manifesting as diarrhoea. Compared with intravenous fluorouracil plus folinic acid (leucovorin) regimens, tegafur/uracil + Calcium Folinate has similar efficacy with less toxicity and is more convenient because it is an oral regimen. Early studies have also shown potential cost savings because of fewer complications.

Zhiqi Song - One of the best experts on this subject based on the ideXlab platform.

  • Homocysteine and psoriasis
    Bioscience reports, 2019
    Co-Authors: Xiran Lin, Xianmin Meng, Zhiqi Song
    Abstract:

    Psoriasis is caused by a complex interplay among the immune system, genetic background, autoantigens, and environmental factors. Recent studies have demonstrated that patients with psoriasis have a significantly higher serum homocysteine (Hcy) level and a higher prevalence of hyperhomocysteinaemia (HHcy). Insufficiency of folic acid and vitamin B12 can be a cause of HHcy in psoriasis. Hcy may promote the immuno-inflammatory process in the pathogenesis of psoriasis by activating Th1 and Th17 cells and neutrophils, while suppressing regulatory T cells. Moreover, Hcy can drive the immuno-inflammatory process by enhancing the production of the pro-inflammatory cytokines in related to psoriasis. Hcy can induce nuclear factor kappa B activation, which is critical in the immunopathogenesis of psoriasis. There may be a link between the oxidative stress state in psoriasis and the effect of HHcy. Hydrogen sulfide (H2S) may play a protective role in the pathogenesis of psoriasis and the deficiency of H2S in psoriasis may be caused by HHcy. As the role of Hcy in the pathogenesis of psoriasis is most likely established, Hcy can be a potential therapeutic target for the treatment of psoriasis. Systemic Folinate Calcium, a folic acid derivative, and topical vitamin B12 have found to be effective in treating psoriasis.

Ping-ying Chang - One of the best experts on this subject based on the ideXlab platform.

  • Univariate Cox regression analysis of 4-year progression-free survival and overall survival of 180 patients with age
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; RR: relative risk; UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

  • Univariate Cox regression analysis of 4-year progression-free survival and overall survival of 108 patients with with old age (≧70) in relation to chemotherapeutic strategies.
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; RR: relative risk; UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

  • The descriptive characteristics and distribution of patients according to chemoregimens.
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    Abbreviations: CEA: carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group performance status; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; No.: number; OXA-based+ 5-FU-based: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; TNM stage: Cancer staging system which was developed and is maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M); UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); w/o: without; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

  • Univariate Cox regression analysis of 4-year progression-free survival and overall survival in relation to patients’ characteristics.
    2015
    Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong Chen
    Abstract:

    a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; CEA: carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group performance status; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/Folinate Calcium or oral capecitabine); P: probability value; RR: relative risk; TNM stage: Cancer staging system which was developed and is maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M); UFUR: oral UFUR/LV, tegafur-uracil/oral Folinate Calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.

Paulo M. Hoff - One of the best experts on this subject based on the ideXlab platform.

  • Tegafur/Uracil + Calcium Folinate in Colorectal Cancer
    Drugs, 1999
    Co-Authors: Paulo M. Hoff, Yvonne Lassere, Richard Pazdur
    Abstract:

    The oral chemotherapeutic agent tegafur/uracil (UFT®) is the first of a new class of anticancer drugs called dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. Tegafur/uracil combines uracil with the fluorouracil prodrug tegafur in a 4: 1 molar ratio. Uracil competitively inhibits the degradation of fluorouracil, which results in the concentration of fluorouracil remaining at sustained levels in both plasma and tumour. Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours. Trials conducted in the US have focused on the combination of tegafur/uracil plus Calcium Folinate (Calcium leucovorin) [ORZEL®]. Several phase I and II trials have evaluated the maximum tolerated dose, pharmacokinetics, efficacy, and safety of this combination in the treatment of colorectal cancer. Results have shown that tegafur/uracil at 300 mg/m^2/day in divided doses given every 8 hours for 28 days provides prolonged exposure to fluorouracil. Furthermore, tegafur/uracil + Calcium Folinate is well tolerated, with dose-limiting toxicity manifesting as diarrhoea. Compared with intravenous fluorouracil plus folinic acid (leucovorin) regimens, tegafur/uracil + Calcium Folinate has similar efficacy with less toxicity and is more convenient because it is an oral regimen. Early studies have also shown potential cost savings because of fewer complications.

  • Tegafur/uracil + Calcium Folinate in colorectal cancer: double modulation of fluorouracil.
    Drugs, 1999
    Co-Authors: Paulo M. Hoff, Yvonne Lassere, Richard Pazdur
    Abstract:

    The oral chemotherapeutic agent tegafur/uracil (UFT®) is the first of a new class of anticancer drugs called dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. Tegafur/uracil combines uracil with the fluorouracil prodrug tegafur in a 4: 1 molar ratio. Uracil competitively inhibits the degradation of fluorouracil, which results in the concentration of fluorouracil remaining at sustained levels in both plasma and tumour. Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours. Trials conducted in the US have focused on the combination of tegafur/uracil plus Calcium Folinate (Calcium leucovorin) [ORZEL®]. Several phase I and II trials have evaluated the maximum tolerated dose, pharmacokinetics, efficacy, and safety of this combination in the treatment of colorectal cancer. Results have shown that tegafur/uracil at 300 mg/m2/day in divided doses given every 8 hours for 28 days provides prolonged exposure to fluorouracil. Furthermore, tegafur/uracil + Calcium Folinate is well tolerated, with dose-limiting toxicity manifesting as diarrhoea. Compared with intravenous fluorouracil plus folinic acid (leucovorin) regimens, tegafur/uracil + Calcium Folinate has similar efficacy with less toxicity and is more convenient because it is an oral regimen. Early studies have also shown potential cost savings because of fewer complications.

  • tegafur uracil Calcium Folinate in colorectal cancer double modulation of fluorouracil
    Drugs, 1999
    Co-Authors: Paulo M. Hoff, Yvonne Lassere, Richard Pazdur
    Abstract:

    The oral chemotherapeutic agent tegafur/uracil (UFT®) is the first of a new class of anticancer drugs called dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines. Tegafur/uracil combines uracil with the fluorouracil prodrug tegafur in a 4: 1 molar ratio. Uracil competitively inhibits the degradation of fluorouracil, which results in the concentration of fluorouracil remaining at sustained levels in both plasma and tumour. Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours. Trials conducted in the US have focused on the combination of tegafur/uracil plus Calcium Folinate (Calcium leucovorin) [ORZEL®]. Several phase I and II trials have evaluated the maximum tolerated dose, pharmacokinetics, efficacy, and safety of this combination in the treatment of colorectal cancer. Results have shown that tegafur/uracil at 300 mg/m2/day in divided doses given every 8 hours for 28 days provides prolonged exposure to fluorouracil. Furthermore, tegafur/uracil + Calcium Folinate is well tolerated, with dose-limiting toxicity manifesting as diarrhoea. Compared with intravenous fluorouracil plus folinic acid (leucovorin) regimens, tegafur/uracil + Calcium Folinate has similar efficacy with less toxicity and is more convenient because it is an oral regimen. Early studies have also shown potential cost savings because of fewer complications.